Evidence map›Paper›PMID 41322196›Full record

ArticleMolecular therapy. Oncology2025

An oncolytic herpesvirus expressing a CXCR4 antagonist interferes with glioblastoma cells' stemness features and migration.

Paolo D'arrigo, Maxime Dubois, Judit Sanchez Gil, Cédric Lassence, Alexandre Hego, Benoit Brouwers, Arnaud Lombard, Bernard Rogister, Virginie Neirinckx, Marielle Lebrun and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Paolo D'arrigoLaboratory of Virology and Immunology, GIGA-Immunobiology, University of Liège, 4000 Liège, Belgium.
Maxime DuboisLaboratory of Virology and Immunology, GIGA-Immunobiology, University of Liège, 4000 Liège, Belgium.
Judit Sanchez GilLaboratory of Virology and Immunology, GIGA-Immunobiology, University of Liège, 4000 Liège, Belgium.
Cédric LassenceLaboratory of Virology and Immunology, GIGA-Immunobiology, University of Liège, 4000 Liège, Belgium.
Alexandre HegoGIGA-Cell Imaging Platform, GIGA, University of Liège, 4000 Liège, Belgium.
Benoit BrouwersLaboratory of Nervous System Disorders and Therapy, GIGA-Neurosciences, University of Liège, 4000 Liège, Belgium.
Arnaud LombardLaboratory of Nervous System Disorders and Therapy, GIGA-Neurosciences, University of Liège, 4000 Liège, Belgium.
Bernard RogisterLaboratory of Nervous System Disorders and Therapy, GIGA-Neurosciences, University of Liège, 4000 Liège, Belgium.
Virginie NeirinckxLaboratory of Nervous System Disorders and Therapy, GIGA-Neurosciences, University of Liège, 4000 Liège, Belgium.
Marielle LebrunLaboratory of Virology and Immunology, GIGA-Immunobiology, University of Liège, 4000 Liège, Belgium.
Catherine Sadzot-DelvauxLaboratory of Virology and Immunology, GIGA-Immunobiology, University of Liège, 4000 Liège, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is one of the most aggressive brain tumors. Despite the standard therapy, the survival from diagnosis remains dramatically low, especially due to tumor recurrence. Glioblastoma stem-like cells (GSCs) have been implicated in this tumor relapse, e.g., based on their capacity to escape the tumor and to migrate through the brain via CXCR4-dependent mechanisms. CXCR4 regulates biological features associated with tumor progression, including self-renewal, migration, and radio resistance. Importantly, its expression correlates with severity and poor prognosis of several cancers including GBM. The CXCR4/CXCL12 pathway therefore appears as an interesting potential therapeutic target. We have generated an oncolytic herpes simplex virus (oHSV) expressing HA-P2G, a mutated form of CXCL12 previously described as a CXCR4 competitive inhibitor. We demonstrate that,

Indexed as

CXCL12/CXCR4CXCR4 antagonistglioblastomaMT: Regular Issueoncolytic herpesvirusvirotherapy

Identifiers

PMID41322196
PMCPMC12663512

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.